nach oben

Current Diabetes Reports

Erschienen in:

01.05.2021 | Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

Diabetes in People with HIV

verfasst von: Sudipa Sarkar, Todd T. Brown

Erschienen in: Current Diabetes Reports | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To discuss the diagnosis, treatment, and complications of diabetes in people with HIV (PWH) and to review HIV-related factors that may contribute to the development of diabetes or alter decisions in the care and treatment of PWH with diabetes.

Recent Findings

For those patients with atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, GLP-1 receptor agonists and SGLT-2 inhibitors should be considered for use. Evidence for this recommendation is, however, based on studies that were not conducted in populations consisting solely of PWH.

Summary

Diabetes is a significant comorbidity in PWH and adds to their already heightened risk of cardiovascular disease. HIV-specific factors, including interactions of antiretroviral therapy with medications that either treat diabetes and/or prevent cardiovascular disease, should be evaluated.

Buchacz K, Baker RK, Palella FJ, et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2013;18(1):65–75.PubMedCrossRef

Warriner AH, Burkholder GA, Overton ET. HIV-related metabolic comorbidities in the current ART era. Infect Dis Clin N Am. 2014;28(3):457-+.CrossRef

Noubissi EC, Katte JC, Sobngwi E. Diabetes and HIV. Curr Diabetes Rep. 2018;18(11).

Patel P, Rose CE, Collins PY, Nuche-Berenguer B, Sahasrabuddhe VV, Peprah E, et al. Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis. Aids. 2018;32:S5–S20.PubMedPubMedCentralCrossRef

Brown TT, Cole SR, Li XH, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med. 2005;165(10):1179–84.PubMedCrossRef

Galli L, Salpietro S, Pellicciotta G, Galliani A, Piatti P, Hasson H, et al. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. European journal of epidemiology. 2012;27(8):657–65.PubMedCrossRef

Prioreschi A, Munthali RJ, Soepnel L, Goldstein JA, Micklesfield LK, Aronoff DM, et al. Incidence and prevalence of type 2 diabetes mellitus with HIV infection in Africa: a systematic review and meta-analysis. BMJ open. 2017;7(3):e013953.PubMedPubMedCentralCrossRef

Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, et al. HIV infection and the risk of diabetes mellitus. Aids. 2009;23(10):1227–34.PubMedPubMedCentralCrossRef

Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis. 2020;33(1):10–9.PubMedPubMedCentralCrossRef

10.

Knudsen AD, Krebs-Demmer L, Bjørge NID, Elming MB, Gelpi M, Sigvardsen PE, et al. Pericardial adipose tissue volume is independently associated with human immunodeficiency virus status and prior use of stavudine, didanosine, or indinavir. The Journal of infectious diseases. 2020;222(1):54–61.PubMedCrossRef

11.

Antonopoulos AS, Antoniades C. The role of epicardial adipose tissue in cardiac biology: classic concepts and emerging roles. The Journal of physiology. 2017;595(12):3907–17.PubMedPubMedCentralCrossRef

12.

Gelpi M, Afzal S, Fuchs A, Lundgren J, Knudsen AD, Drivsholm N, et al. Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. Aids. 2019;33(4):675–83.PubMedCrossRef

13.

Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. Aids. 2003;17(7):971–9.PubMedCrossRef

14.

https://clinicalinfo.hiv.gov/sites/default/files/inline-files/AdultandAdolescentGL.pdf. Accessed (October 3, 2020). PoAGfAaAGftUoAAiAaAwHDoHaHSAa.

15.

Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;71(6):1379–89.CrossRef

16.

Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. New Engl J Med. 2019;381(9):803–15.PubMedCrossRef

17.

Kim PS, Woods C, Georgoff P, Crum D, Rosenberg A, Smith M, et al. A1C underestimates glycemia in HIV infection. Diabetes Care. 2009;32(9):1591–3.PubMedPubMedCentralCrossRef

18.

Assoc AD. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S14–31.CrossRef

19.

Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2020 executive summary. Endocr Pract. 2020;26(1):107–39.PubMedCrossRef

20.

5. Facilitating behavior change and well-being to improve health outcomes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S48-s65.

21.

Weiss JJ, Sanchez L, Hubbard J, Lo J, Grinspoon SK, Fitch KV. Diet quality is low and differs by sex in people with HIV. The Journal of nutrition. 2019;149(1):78–87.PubMedPubMedCentralCrossRef

22.

Arnett DK, Khera A, Blumenthal RS. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: Part 1, Lifestyle and behavioral factors. Jama Cardiol. 2019;4(10):1043–4.PubMedCrossRef

23.

Schuelter-Trevisol F, Wolff FH, Alencastro PR, et al. Physical activity: do patients infected with HIV practice? How much? A systematic review. Current HIV research. 2012;10(6):487–97.PubMedCrossRef

24.

Vancampfort D, Mugisha J, Richards J, De Hert M, Probst M, Stubbs B. Physical activity correlates in people living with HIV/AIDS: a systematic review of 45 studies. Disability and rehabilitation. 2018;40(14):1618–29.PubMedCrossRef

25.

Assoc AD. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020 (vol 43, pg S98, 2020). Diabetes Care. 2020;43(8):1979.CrossRef

26.

Custodio J, West S, Yu A, Martin H, Graham H, Quirk E, et al. Lack of clinically relevant effect of bictegravir (BIC, B) on metformin (MET) pharmacokinetics (PK) and pharmacodynamics (PD). Open forum infectious diseases. 2017;4(Suppl 1):S429.PubMedCentralCrossRef

27.

Han JH, Gordon K, Womack JA, Gibert CL, Leaf DA, Rimland D, et al. Comparative effectiveness of diabetic oral medications among HIV-infected and HIV-uninfected veterans. Diabetes Care. 2017;40(2):218–25.PubMedCrossRef

28.

Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33(8):1859–64.PubMedPubMedCentralCrossRef

29.

Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, et al. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. The Journal of clinical endocrinology and metabolism. 2017;102(3):914–22.PubMed

30.

Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, et al. Thiazolidinedione use and bone loss in older diabetic adults. The Journal of clinical endocrinology and metabolism. 2006;91(9):3349–54.PubMedPubMedCentralCrossRef

31.

Ferwana M, Firwana B, Hasan R, al-Mallah MH, Kim S, Montori VM, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabetic medicine : a journal of the British Diabetic Association. 2013;30(9):1026–32.CrossRef

32.

Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ (Clinical research ed). 2016;352:i1541.

33.

Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. Jama. 2015;314(3):265–77.PubMedCrossRef

34.

Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the risk of bladder cancer: a meta-analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2017;8(4):705–26.CrossRef

35.

Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–95.PubMedPubMedCentralCrossRef

36.

Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.CrossRef

37.

Maggi P, Di Biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. Bmc Infect Dis. 2017;17:551.PubMedPubMedCentralCrossRef

38.

Koutkia P, Grinspoon S. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Annual review of medicine. 2004;55:303–17.PubMedCrossRef

39.

Yarasheski KE, Cade WT, Overton ET, Mondy KE, Hubert S, Laciny E, et al. Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. American journal of physiology Endocrinology and metabolism. 2011;300(1):E243–51.PubMedCrossRef

40.

Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, Boutekatjirt A, et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther. 2008;13(1):67–76.PubMedCrossRef

41.

Calmy A, Hirschel B, Hans D, Karsegard VL, Meier CA. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. Aids. 2003;17(5):770–2.PubMedCrossRef

42.

Gomez-Peralta F, Abreu C, Gomez-Rodriguez S, Barranco RJ, Umpierrez GE. Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: an updated review and challenging clinical scenarios. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2018;9(5):1775–89.CrossRef

43.

Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes spectrum : a publication of the American Diabetes Association. 2017;30(3):202–10.CrossRef

44.

Gallwitz B. Clinical use of DPP-4 inhibitors. Frontiers in endocrinology. 2019;10:389.PubMedPubMedCentralCrossRef

45.

Onglyza (saxagliptin) - FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf. Accessed November 30.

46.

Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Critical reviews in clinical laboratory sciences. 2003;40(3):209–94.PubMedCrossRef

47.

Goodwin SR, Reeds DN, Royal M, Struthers H, Laciny E, Yarasheski KE. Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study. The Journal of clinical endocrinology and metabolism. 2013;98(2):743–51.PubMedCrossRef

48.

Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, et al. Sitagliptin exerts an antinflammatory action. The Journal of clinical endocrinology and metabolism. 2012;97(9):3333–41.PubMedPubMedCentralCrossRef

49.

Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism: clinical and experimental. 2014;63(9):1141–8.CrossRef

50.

Dube MP, Chan ES, Lake JE, et al. A randomized, double-blinded, placebo-controlled trial of sitagliptin for reducing inflammation and immune activation in treated and suppressed human immunodeficiency virus infection. Clinical Infectious Diseases. 2019;69(7):1165–72.PubMedCrossRef

51.

Aroda VR. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes, obesity & metabolism. 2018;20(Suppl 1):22–33.CrossRef

52.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. The New England journal of medicine. 2016;375(4):311–22.PubMedPubMedCentralCrossRef

53.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. The New England journal of medicine. 2016;375(19):1834–44.PubMedCrossRef

54.

Diamant M, van Agtmael M. Liraglutide treatment in a patient with HIV and uncontrolled insulin-treated type 2 diabetes. Diabetes Care. 2012;35(5):e34.PubMedPubMedCentralCrossRef

55.

García de Lucas MD, Olalla Sierra J, Piña Fernández J. Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome. Diabetes & metabolism. 2015;41(1):102–3.CrossRef

56.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England journal of medicine. 2015;373(22):2117–28.PubMedCrossRef

57.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. The New England journal of medicine. 2019;380(4):347–57.PubMedCrossRef

58.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. The New England journal of medicine. 2017;377(7):644–57.PubMedCrossRef

59.

Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL Jr, Kalyani RR, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(9):1117–45.PubMedPubMedCentralCrossRef

60.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. The New England journal of medicine. 2019;380(24):2295–306.PubMedCrossRef

61.

García de Lucas MD, Olalla J. Experience of using ISGTL-2 in patients with DM2 and HIV infection. European journal of internal medicine. 2017;41:e29.PubMedCrossRef

62.

Kaarsholm NC, Lin S, Yan L, Kelly T, van Heek M, Mu J, et al. Engineering glucose responsiveness into insulin. Diabetes. 2018;67(2):299–308.PubMedCrossRef

63.

Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107–39.PubMedCrossRef

64.

Kaku M, Simpson DM. HIV neuropathy. Curr Opin Hiv Aids. 2014;9(6):521–6.PubMedCrossRef

65.

Assoc AD. Microvascular complications and foot care: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S135–51.CrossRef

66.

"Burden of Vision Loss." https://www.cdc.gov/visionhealth/risk/burden.htm. Accessed October 2.

67.

Skiest DJ. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART). Am J Med Sci. 1999;317(5):318–35.PubMedCrossRef

68.

Goldberg DE, Smithen LM, Angelilli A, Freeman WR. HIV-associated retinopathy in the HAART era. Retina-J Ret Vit Dis. 2005;25(5):633–49.

69.

Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018;71(6):884–95.PubMedCrossRef

70.

Cohen SD, Kopp JB, Kimmel PL. Kidney diseases associated with human immunodeficiency virus infection. New Engl J Med. 2017;377(24):2363–74.PubMedCrossRef

71.

Palella FJ Jr, Li X, Gupta SK, et al. Long-term kidney function, proteinuria, and associated risks among HIV-infected and uninfected men. Aids. 2018;32(10):1247–56.PubMedPubMedCentralCrossRef

72.

10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S111-s134.

73.

Grinspoon SK, Fitch KV, Overton ET, Fichtenbaum CJ, Zanni MV, Aberg JA, et al. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J. 2019;212:23–35.PubMedPubMedCentralCrossRef

Titel: Diabetes in People with HIV
verfasst von: Sudipa Sarkar
Todd T. Brown
Publikationsdatum: 01.05.2021
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 5/2021
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-021-01382-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen